In November, Longeveron completed enrollment in its Phase 2a trial of Lomecel-B TM for the treatment of Alzheimer’s Disease (AD). We anticipate randomizing the first patient in this study before the end of the first quarter. The trial is being conducted in partnership with the National Center for Geriatrics & Gerontology (NCGG Nagoya) and Juntendo University Hospital (Tokyo). The trial is expected to enroll 45 patients and has a primary objective of evaluating safety of Lomecel-B TM as a treatment for Aging-Related Frailty. The Phase 2 Clinical trial is a 3-arm, parallel design, randomized (1:1:1), placebo-controlled, double-blind single infusion study of two different dose levels of Lomecel-B TM. The Company has initiated Phase 2 Clinical trial of Lomecel-B TM for Aging-Related Frailty in Japan. Enrollment is ongoing in the ELPIS II trial, a 38-patient, randomized (1:1), blinded, controlled Phase 2 clinical trial intended to evaluate the safety and efficacy of intramyocardial injection of Lomecel-B TM in infants with HLHS who are undergoing Stage 2 surgery. In January 2023, the full results of the ELPIS I Trial of Lomecel-B TM for hypoplastic left heart syndrome (HLHS) were published in European Heart Journal Open. Lomecel-B TM for Hypoplastic Left Heart Syndrome (HLHS): We look forward to building on this progress through the rest of 2023.”īusiness Highlights and Anticipated Milestones: We have also made progress with our Japan Aging-Related Phase 2 study. We are excited to continue advancing this opportunity through our ongoing Phase 2 ELPIS II trial. “Earlier this year, the full data from our ELPIS I trial of Lomecel-B TM for infants with HLHS was published in European Heart Journal Open. “Longeveron had a productive 2022, executing on multiple key milestones as we continued to advance Lomecel-B TM for multiple indications,” said Wa’el Hashad, Chief Executive Officer. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022. MIAMI, Ma(GLOBE NEWSWIRE) - Longeveron Inc. 
Conference call scheduled for 8:30 a.m. First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – Full results from ELPIS I trial published in European Heart Journal Open –
0 kommentar(er)
